TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to cut heart deaths in rare amyloidosis
Disease control Recruiting nowThis study tests an experimental drug called nucresiran in people with a rare disease that causes abnormal protein buildup in the heart (ATTR amyloidosis with cardiomyopathy). The goal is to see if the drug can lower the risk of death and serious heart events compared to a placeb…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
Real-World study tracks heart patients on new drug
Knowledge-focused Recruiting nowThis study follows 2,000 adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) who are starting vutrisiran or another approved therapy. Researchers will observe how the disease progresses, how patients feel, and what treatments they receive in routine medical care. …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 06:47 UTC